We are pleased that Dr. Modjtahedi found our work on GA201 interesting. The origin of the CDR sequences of GA201 based on the published sequences of the ICR62 antibody is clearly mentioned in our publication (1). Likewise, previous publications describing the properties of ICR62 were also cited in the article.
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Percent survival Figure 2 . Superior efficacy of GA201 versus cetuximab and the wild type, nonglycoengineered version of GA201 in the A549 lung adenocarcinoma xenograft model in SCID/beige mice. All animals (n ¼ 10 per treatment group) were treated therapeutically with 25 mg/kg antibody once weekly for 3 weeks. Dosing began on day 7 after injection of tumor cells, once tumor was detectable. The data show that GA201 achieved a significantly superior median OS compared with cetuximab, and the wild type nonglycoengineered version of GA201.
